trial

A PET Study With RO5545965 in Healthy Male Volunteers

NCTId NCT01923025
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 9 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2013-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
9 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-08
Primary completion
2013-11
Eligibility
MALE · 25 Years · 50 Years

Interventions & indications

Drugs
RO5545965

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
9
Phase
PHASE1
Primary Completion Date
2013-11
Status
COMPLETED
relationships
The graph out of here
drug
RO5545965
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication